Most Recent
King & Wood Mallesons has appointed a former Corrs Chambers Westgarth partner to join its intellectual property practice in Melbourne.
Journalist Tegan George will add sex discrimination claims against Network Ten to her lawsuit that alleges harassment and bullying by political journalist Peter van Onselen.
Global firm Clifford Chance has lured a Corrs Chambers Westgarth litigation partner to meet the increased demand for projects expertise stemming from pandemic-related construction disputes.
The Full Federal Court was emphatic in its decision that the environment minister does not owe a duty of care to Australian children to shield them from climate change harm, but there is no doubt the law will be put to the test again soon, says Corrs Chambers Westgarth's Louise Camenzuli, Julia Green and Max Newman.
A former Salter Brothers client has filed a lawsuit against the fund manager, claiming it misled her about an investment fund marketed as part of a visa program to migrate to Australia.
A bid by the liquidators of collapsed engineering company Hastie Group for Lendlease to pay back funds it withdrew under bank guarantees is “untenable” and “misconceived”, a court has heard in a $68 million case that also targets Multiplex, Grocon and John Holland.
A judge has signed off on a settlement in a trade mark spat between M&M candy maker Mars and the world's largest macadamia grower, Macquis Macadamias, under which Marquis will no longer seek to register its MM mark for chocolate bars.
Even after 30 years in action, the future of class actions in Australia remains uncertain. What is clear, however, is the impact class actions have had – for claimants, lawyers, litigation funders and for corporate Australia, writes Corrs Chambers Westgarth's Chris Pagent, Brad Woodhouse, Alex Ji and Thomas Scott.
The Canberra developer behind the Manhattan on the Park apartment building in the national capital has been hit with a class action on behalf of home buyers who were allegedly misled into paying GST on the price of their property.
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck's patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.